Solubility Enhancement of Aceclofenac Using Dendrimer

 

Kevin C Garala, Anil J Shinde* and Harinath N More

Department of Pharmaceutics, Bharati Vidyapeeth College of Pharmacy, Kolhapur, Maharashtra, India.

 

ABSTRACT

In the present study we investigated the effect of generation 3 (G3) PAMAM dendrimer on the aqueous solubility of aceclofenac. The aqueous solubility of aceclofenac was measured in the presence of dendrimer. A 32 full factorial design was employed. The concentration of dendrimer and temperature were used as independent variables, while solubility of drug was selected as dependent variable. The experimental results showed that the aqueous solubility of aceclofenac was directly proportional to concentration of dendrimer and inversely proportional to the temperature under the experiment performed. Under the suitable condition, the solubility of aceclofenac can improves with the PAMAM dendrimer.

 

KEYWORDS:  Dendrimers, G3 PAMAM dendrimer, 32 full factorial design, Solubility enhancement.

 

1. INTRODUCTION

Dendrimer, also called arborols or cascade molecules1 or artificial proteins2, is derived from the Greek words dendron (tree) and meros (part) 3. They are monodisperse, well-defined artificial macromolecules which have highly branched, three-dimensional features that resemble the architecture of a tree, having defined molecular weight and host-guest entrapment properties4. The highly branched molecular structure of dendrimers, which resembles Christmas stars, ice crystals, or treetops5. A typical dendrimer consists of three basic components (Figure 1): a central core from which the polymeric branches emanate; repeat units the nature of which determines the microenvironment of the interior and in turn the solubilization ability of the dendrimer; and the terminal surface groups, the nature and number of these groups are mostly responsible for the performance of dendrimers in solution6. The branched units are prearranged in layers called ‘‘generations’’ and correspond to the repeating monomer unit of these macromolecules3.

 

Dendrimers are divided into two families, compact and extended dendrimers7. They are prepared through divergent or convergent iterative procedures to obtained different sizes or generations8. Polyamidoamine (PAMAM) dendrimers are founded on an ethylenediamine core, and branched units are constructed from methyl acrylate and ethylenediamine6. PAMAM dendrimers are biocompatible, nonimmunogenic water-soluble, and possess terminal modifiable amine functional groups for binding various guest molecules9. Hydrophobic drugs can be interacted with the dendrimer to make them water10. Drugs can either be attached to dendrimers end groups or encapsulated in the macromolecule interior11. The high density of amino groups and special structure in PAMAM dendrimers may be projected to have potential applications in enhancing the solubility of the low aqueous soluble drugs12.

 

Aceclofenac, a phenylacetic acid derivative, non-steroidal anti-inflammatory drug (NSAID), used in the management of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. Though, the use of such drugs is restricted by their significant toxicity. The commonest adverse effects of NSAIDs are usually gastrointestinal disturbances13, such as gastrointestinal discomfort, nausea, and diarrhoea. It is clear that usually most NSAIDs can damage the esophagus, stomach, duodenum, small intestine and large intestine14.


Fig. 1: Structure of Dendrimer

 

It was suggested that the use of NSAIDs in parenteral could control these proven side effects. But due to poor aqueous solubility of NSAIDs, their use in topical and parenteral formulation has also been limited. The poor aqueous solubility of drug is generally related to a low bioavailability, so it needs to increase the aqueous solubility of such drugs15.

 

The solubility of Nifedipine9, Ibuprofen16, nicotinic acid17, ketoprofen18, furosemide19 has been tested with dendrimer. In the present study we investigated the effect of concentration of G3 PAMAM dendrimer and temperature to increase the solubility of hydrophobic drug, aceclofenac.

 

MATERIALS AND METHODS:

Materials:

Aceclofenac was a gift sample from Rantus Pharma Pvt Ltd. (Hyderabad, India).  G3 PAMAM dendrimer was a gift sample from Dendritech Inc. (USA). All other ingredients used were of pharmaceutical grade.

 

Methods:

Solubility testing experiments:

The solubility of aceclofenac in G3 PAMAM dendrimer solutions in 1, 2 and 3 % w/v was determined at constant neutral pH. Excess ibuprofen was added to 10 ml vials containing 5 ml of each test solution. The vials were then incubated in an orbital shaking incubator for 24 h. Then the solutions were filtered through a 0.45 µm filter (Sartorius) and the amount of aceclofenac in the filtrate determined by UV spectrophotometer at 245 nm. The effect of temperature on solubility was examined over the range 25, 37 and 45°C.

 

Fig.2: Response surface plot

 

Table 1: Full factorial experimental design layout

Trials

Variable level in coded form

X1

X2

1

-1

-1

2

-1

0

3

-1

1

4

0

-1

5

0

0

6

0

1

7

1

-1

8

1

0

9

1

1

 

 

 

 

 

 

 

 

 

 

 

 

Factorial Design:

A 32 full-factorial design was constructed to study the effect of dendrimer and temperature on the solubility of drug. In this study, two factors were evaluated, each at three levels; experimental trials were performed at all 9 possible combinations (Table 1). The percentage of G3 dendrimer (X1) and temperature (X2) were selected as independent variables. The solubility of drug was selected as dependent variable. The data were subjected to 3-D response surface methodology in PCP Disso 2.08 to determine the effect of dendrimer and temperature on the solubility of drug, dependent variable. The values of variables in a 32 factorial design are indicated in Table 2. A statistical model incorporating interactive and polynomial terms was used to calculate the responses.

 

Y = bo + b1X1 + b2X2 + b12X1X2 + b11X12 + b22X22……..(1)

 

Where, Y is the dependent variable, bo is the arithmetic mean response of the 9 trials, and bi (b1, b2, b12, b11 and b22) is the estimated coefficient for the corresponding factor Xi (X1, X2, X1X2, X12 and X22), which represents the average result of changing 1 factor at a time from its low to high value. The interaction term (X1X2) shows how the response changes when 2 factors are simultaneously changed. The polynomial terms (X12 and X22) are included to investigate the nonlinearity.

 

 

Table 2: Values Amount of Variables in a 32 Factorial Design

Coded Values

Actual Values

X1 = Dendrimer Solution % (w/v)

X2 = Temperature (ºC)

-1

1

25

0

2

37

1

3

45

 

Table 3: Result of Solubility testing

Trials

Solubility (mg/ml)

1

8.37

2

7.53

3

6.72

4

15.76

5

13.52

6

10.43

7

17.12

8

14.08

9

12.11

 

RESULTS:

Solubility testing:

The solubility experiments of aceclofenac were carried out using G3 PAMAM dendrimer of molecular weight 6,909 Dalton and 32 amine groups on the exterior of molecules, and the results were shown in Table 3. It was observed that the solubility of aceclofenac increased considerably with PAMAM concentrations. In the presence of G3 PAMAM dendrimer at a fixed pH state, the solubility of aceclofenac in the dendrimer solutions increased with an increase in

 

dendrimer concentration. Fig. 2 shows that the amount of aceclofenac dissolved in G3 PAMAM dendrimers was inversely proportional to the temperature. The cause of this effect is not clear.

 

Factorial Design:

The solubility of drug for the 9 trials showed a wide variation (i.e., from 6.72 to 17.12 mg/ml). The response of various trials according to the 32 factorial designs shown in Table 3. The data clearly imply that the solubility of drug is effectively dependent on the chosen independent variables. The fitted equations relating the response to the transformed factor shown in equation 2.

 

Final Equation in Terms of Coded values:

Y = 13.2367 + 3.4483 X1 – 1.9983 X2 – 2.2483 X12 .. (2)

 

Fig. 2 shows the plot of the percentage of G3 dendrimer (X1) and the temperature (X2) vs solubility (mg/ml). The response surface plot was drawn using PCP Disso V 2.08. The data demonstrate that both X1 and X2 affect the drug solubility. It is concluded that a maximum concentration of dendrimer at low temperature favors the significant improvement of solubility of drug.

 

DISCUSSION:

The G3 PAMAM dendrimers have the ability to significantly enhance the solubility of poorly water-soluble drug, aceclofenac. These may be due to the interactions between the surface amine groups of dendrimer molecule and the carboxyl group of aceclofenac. The drug solubility is directly proportional to the concentration of the dendrimer, this was most probably due to the increase in the number of surface amines that are available to interact electrostatically with aceclofenac molecules, and inversely proportional to the temperature.

 

ACKNOWLEDGEMENT:

We are thankful to Rantus Pharma Pvt. Ltd. (Hyderabad, India) for providing gift sample of aceclofenac. We are grateful to Dendritech Inc. (USA) for the gift sample of dendrimer.

 

REFERENCES:

1.       Duncan R and Izzo L. Dendrimer biocompatibility and toxicity. Adv Drug Deliv Rev. 2005; 57: 2215-2237.

2.       Svenson S and Tomalia DA. Dendrimers in biomedical applications-reflections on the field. Adv Drug Deliv Rev. 2005; 57: 2106-2129.

3.       Aulenta F, Hayes W and Rannard S. Dendrimers: a new class of nanoscopic containers and delivery devices. Eur Polym J. 2003; 39: 1741-1771.

4.       Cheng YY and Xu TW. Dendrimers as potential drug carriers. Part I. solubilization of non-steroidal anti-inflammatory drugs in the presence of polyamidoamine dendrimers. Eur J Med Chem. 2005; 40: 1188-1192.

5.       Vogtle F, Gestermann S, Hesse R, Schwierz H and Windisch B. Functional dendrimers. Prog Polym Sci. 2000; 25: 987-1041.

6.       Tomalia DA, Baker H, Dewald J, Hall M, Kallos G, Martin S, Roeck J, Ryder J and Smith P. A new class of polymers: starbust-dendrimtic macromolecules. Polym J. 1985; 17: 117-132.

7.       Supritz C, Engelmann A and Reineker P. Optical absorption in dendrimers. J Lumin. 2004; 110: 122–123.

8.       Maes W, Verstappen B and Dehaen W. Synthesis of 1,2,4-triazole dendrimers. Tetrahedron. 2006; 62: 2677-2683.

9.       Devarakonda B, Hill RA and de Villiers MM. The effect of PAMAM dendrimer generation size and surface functional group on the aqueous solubility of nifedipine. Int J Pharm. 2004; 284: 133-140.

10.    Patri AK, Kukowska-Latallo JF and Baker Jr JR. Targeted drug delivery with dendrimers: Comparison of the release kinetics of covalently conjugated drug and non-covalent drug inclusion complex. Adv Drug Deliv Rev. 2005; 57: 2203-2214.

11.    Furuta P and Frechet JM. Controlling solubility and modulating peripheral function in dendrimer encapsulated dyes. J Am Chem Soc. 2003; 125: 13173-13181.

12.    Newkome GR, Moorefield CN and Baker GR. Alkane cascade polymers processing micellar topology: micellanoic acid derivatives. Angew Chem Int Ed Engl. 1991; 30: 1178-1180.

13.    Marie RG. Nonsteroidal anti-inflammatory drugs: Practical and theoretical considerations in their selection. Am J Med. 1996; 100: 31S.

14.    Denis MM. Comparative toxicity of nonsteroidal anti-inflammatory drugs.  Am J Med. 1999; 107: 37S.

15.    Fabrice L, Fabienne P and Myriam M. Binding of ketoprofen enantiomers in various human albumin preparations. J Pharm Biomed Anal. 2000; 23: 793-802.

16.    Milhem OM,  Myles C, McKeown NB, Attwood D and  D’Emanuele A. Polyamidoamine Starburst® dendrimers as solubility enhancers. Int J Pharm. 2000; 197: 239-241.

17.    Yiyun C and Tongwen Xu. Solubility of nicotinic acid in polyamidoamine dendrimer solutions. Eur J Med Chem. 2005; 40: 1384-1389.

18.    Yiyun C, Tongwen Xu and Rongqiang Fu. Polyamidoamine dendrimers used as solubility enhancers of ketoprofen. Eur J Med Chem. 2005; 40: 1390-1393.

19.    Devarakonda B, Otto DP, Judefeind A, Hill RA and de Villiers MM. Effect of pH on the solubility and release of furosemide from polyamidoamine (PAMAM) dendrimer complexes. Int J Pharm. 2007; 345: 142-153.

 

 

 

Received on 06.03.2009

Accepted on 12.08.2009     

© A &V Publication all right reserved

Research Journal of Pharmaceutical Dosage Forms and Technology. 1(2): Sept.-Oct. 2009, 94-96